LATS2 and ovarian cancer: Interestingly, TCGA RNASeqV2 data for serous high-grade ovarian cancer showed that both LATS1 and LATS2 expressions were associated with a higher risk for poorer survival (HR = 1.14 for LATS1 and HR = 1.08 for LATS2) for this more homogenous group of patients.